vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and REED'S, INC. (REED). Click either name above to swap in a different company.
Arbutus Biopharma Corp is the larger business by last-quarter revenue ($10.7M vs $7.5M, roughly 1.4× REED'S, INC.). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs -50.5%, a 74.0% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs -23.1%). Over the past eight quarters, REED'S, INC.'s revenue compounded faster (-11.7% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Waddell & Reed Financial, Inc. was an American asset management and financial planning company founded in 1937 in Kansas City, Missouri. It was a publicly traded company from 1998 to 2021, and briefly had its headquarters in Overland Park, Kansas, and was planning a move back to Downtown Kansas City before the company was sold. It operated asset management and distribution subsidiaries, including Ivy Investment Management Company and Waddell & Reed Investment Management Company.
ABUS vs REED — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $7.5M |
| Net Profit | $2.5M | $-3.8M |
| Gross Margin | — | 20.4% |
| Operating Margin | 13.9% | -46.9% |
| Net Margin | 23.5% | -50.5% |
| Revenue YoY | 522.2% | -23.1% |
| Net Profit YoY | 112.7% | 8.2% |
| EPS (diluted) | $0.01 | $-1.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $7.5M | ||
| Q3 25 | — | $7.0M | ||
| Q2 25 | $10.7M | $9.5M | ||
| Q1 25 | — | $10.0M | ||
| Q4 24 | — | $9.7M | ||
| Q3 24 | — | $6.8M | ||
| Q2 24 | — | $11.9M | ||
| Q1 24 | — | $9.6M |
| Q4 25 | — | $-3.8M | ||
| Q3 25 | — | $-4.0M | ||
| Q2 25 | $2.5M | $-6.0M | ||
| Q1 25 | — | $-2.0M | ||
| Q4 24 | — | $-4.1M | ||
| Q3 24 | — | $-4.2M | ||
| Q2 24 | — | $-3.2M | ||
| Q1 24 | — | $-1.7M |
| Q4 25 | — | 20.4% | ||
| Q3 25 | — | 17.4% | ||
| Q2 25 | — | 8.5% | ||
| Q1 25 | — | 33.9% | ||
| Q4 24 | — | 30.0% | ||
| Q3 24 | — | 18.0% | ||
| Q2 24 | — | 32.3% | ||
| Q1 24 | — | 35.6% |
| Q4 25 | — | -46.9% | ||
| Q3 25 | — | -58.3% | ||
| Q2 25 | 13.9% | -60.8% | ||
| Q1 25 | — | -17.4% | ||
| Q4 24 | — | -37.6% | ||
| Q3 24 | — | -46.5% | ||
| Q2 24 | — | -5.6% | ||
| Q1 24 | — | -6.8% |
| Q4 25 | — | -50.5% | ||
| Q3 25 | — | -56.6% | ||
| Q2 25 | 23.5% | -63.5% | ||
| Q1 25 | — | -20.3% | ||
| Q4 24 | — | -42.3% | ||
| Q3 24 | — | -61.5% | ||
| Q2 24 | — | -27.1% | ||
| Q1 24 | — | -17.4% |
| Q4 25 | — | $-1.26 | ||
| Q3 25 | — | $-0.48 | ||
| Q2 25 | $0.01 | $-0.13 | ||
| Q1 25 | — | $-0.04 | ||
| Q4 24 | — | $-3.73 | ||
| Q3 24 | — | $-4.91 | ||
| Q2 24 | — | $-0.77 | ||
| Q1 24 | — | $-0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | — |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $9.2M |
| Total Assets | $103.3M | $23.3M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $37.4M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $9.2M | ||
| Q3 25 | — | $2.8M | ||
| Q2 25 | $83.0M | $1.7M | ||
| Q1 25 | — | $4.7M | ||
| Q4 24 | — | $6.6M | ||
| Q3 24 | — | $-22.0M | ||
| Q2 24 | — | $-23.8M | ||
| Q1 24 | — | $-20.7M |
| Q4 25 | — | $23.3M | ||
| Q3 25 | — | $19.9M | ||
| Q2 25 | $103.3M | $23.7M | ||
| Q1 25 | — | $24.5M | ||
| Q4 24 | — | $25.1M | ||
| Q3 24 | — | $15.0M | ||
| Q2 24 | — | $18.7M | ||
| Q1 24 | — | $19.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $-3.8M |
| Free Cash FlowOCF − Capex | — | $-3.9M |
| FCF MarginFCF / Revenue | — | -52.0% |
| Capex IntensityCapex / Revenue | 0.0% | 1.1% |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-17.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-3.8M | ||
| Q3 25 | — | $-2.8M | ||
| Q2 25 | $-15.7M | $-5.0M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $-3.9M | ||
| Q3 24 | — | $1.1M | ||
| Q2 24 | — | $-912.0K | ||
| Q1 24 | — | $-2.4M |
| Q4 25 | — | $-3.9M | ||
| Q3 25 | — | $-2.9M | ||
| Q2 25 | — | $-5.1M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $-4.0M | ||
| Q3 24 | — | $1.0M | ||
| Q2 24 | — | $-924.0K | ||
| Q1 24 | — | $-2.4M |
| Q4 25 | — | -52.0% | ||
| Q3 25 | — | -41.5% | ||
| Q2 25 | — | -53.2% | ||
| Q1 25 | — | -54.2% | ||
| Q4 24 | — | -40.8% | ||
| Q3 24 | — | 15.3% | ||
| Q2 24 | — | -7.8% | ||
| Q1 24 | — | -25.1% |
| Q4 25 | — | 1.1% | ||
| Q3 25 | — | 1.4% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | — | 0.7% | ||
| Q4 24 | — | 1.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
